Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Kanda

Showing results (341-350 of 355) with videos related to

Pageof 36
Sort By:
Bone Marrow Transplantation|November 13, 2001
Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantationY Kanda, S Mineishi, T Saito, et al.
Haematologica|October 17, 2001
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfanH Niiya, Y Kanda, T Saito, et al.
Bone Marrow Transplantation|July 3, 2003
High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphomaT E Tanimoto, E Kusumi, T Hamaki, et al.
Bone Marrow Transplantation|March 10, 2005
Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patientsT Hamaki, M Kami, Y Kanda, et al.
Bone Marrow Transplantation|October 9, 2012
Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCTM Sato, H Nakasone, K Oshima, et al.
Bone Marrow Transplantation|April 21, 2001
Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in JapanY Kanda, S Mineishi, T Saito, et al.
Bone Marrow Transplantation|August 23, 2005
Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 yearsR Kojima, M Kami, Y Kanda, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 5, 2014
Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantationR Yamazaki, Y Tanaka, H Nakasone, et al.
Bone Marrow Transplantation|January 15, 2014
Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantationM Sato, H Nakasone, K Terasako-Saito, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 12, 2015
Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseasesS-I Kimura, T Murata, Y Akahoshi, et al.
Pageof 36

Showing results (341-350 of 355) with videos related to

Sort By:
Pageof 36
Bone Marrow Transplantation|November 13, 2001
Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantationY Kanda, S Mineishi, T Saito, et al.
Haematologica|October 17, 2001
Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfanH Niiya, Y Kanda, T Saito, et al.
Bone Marrow Transplantation|July 3, 2003
High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphomaT E Tanimoto, E Kusumi, T Hamaki, et al.
Bone Marrow Transplantation|March 10, 2005
Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patientsT Hamaki, M Kami, Y Kanda, et al.
Bone Marrow Transplantation|October 9, 2012
Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCTM Sato, H Nakasone, K Oshima, et al.
Bone Marrow Transplantation|April 21, 2001
Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in JapanY Kanda, S Mineishi, T Saito, et al.
Bone Marrow Transplantation|August 23, 2005
Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 yearsR Kojima, M Kami, Y Kanda, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 5, 2014
Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantationR Yamazaki, Y Tanaka, H Nakasone, et al.
Bone Marrow Transplantation|January 15, 2014
Prediction of infectious complications by the combination of plasma procalcitonin level and localized infection before allogeneic hematopoietic cell transplantationM Sato, H Nakasone, K Terasako-Saito, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 12, 2015
Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseasesS-I Kimura, T Murata, Y Akahoshi, et al.
Pageof 36